secwatch.observer — SEC 8-K summary
======================================

Issuer:     Talis Biomedical Corp (—)
CIK:        0001584751
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091874
Event type: leadership
Sentiment:  negative
Materiality: 0.95
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Talis Biomedical adds restructuring directors, authorizes potential Ch. 11 filing
--------------------------------------------------------------------------------

- Director Heinrich Dreismann resigned effective Aug 1, 2024; Patricia Ferrari and John T. Young Jr. elected.
- New Special Restructuring Committee (Ferrari, Young) authorized to settle securities class action, file Ch. 11, and investigate officer/director claims.
- Ferrari and Young each receive $35,000/month guaranteed for at least 6 months or until bankruptcy plan confirmed.
- Young receives $10,000/yr as Audit Committee chair; both have deep bankruptcy and liquidation experience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/0000950170-24-091874-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1584751/000095017024091874/tlis-20240731.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091874

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer